Do GLP-1 Agonists Slow Progression of Renal Disease in Patients with Type 2 Diabetes?
For patients with type 2 diabetes, several glucagon-like peptide-1 (GLP-1) agonists are U.S. FDA-approved to lower cardiovascular (CV) risk but not …
For patients with type 2 diabetes, several glucagon-like peptide-1 (GLP-1) agonists are U.S. FDA-approved to lower cardiovascular (CV) risk but not …
